Aggressive non-Hodgkin's lymphoma - Long-term survival for all patients?

Haematologica Meeting Reports

Volumn 1, Issue 4, 2007, Pages 27-41

  Coiffier, Bertrand ^a   Tabacof, Jacques ^b   Shen, Zhi Xiang ^c   Jäger, Ulrich ^d  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 46749139997     PISSN: 19707339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl 2007; 5-14.
2. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program) 2004; 221-236.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
4. Sweetenham JW. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology (Am Soc Hematol Educ Program) 2005; 252-259.
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-511.
6. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-1947.
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68-74.
8. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350:1828-1837.
9. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107:4207-4213.
10. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101:4279-4284.
11. Wilson WH, Dunleavy K, Pittaluga S, et al. DA-EPOCH-R is highly effective in both BCL-6+ and BCL-6- untreated de novo diffuse large B-cell lymphoma (DLBCL): study update and analysis of survival outcomes for multiple biomarkers. Blood 2006; 108:Abstract 206.
12. Farinha P, Sehn L, Skinnider B, et al. Strong p53 expression is an independent predictor of outcome in de novo diffuse large B cell lymphoma (DLBCL) treated with either CHOP or CHOP-R. Blood 2006; 108:Abstract 812.
13. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109:1857-1861.
14. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
15. Sonneveld P, de Ridder M, Van der LH, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13:2530-2539.
16. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102:4284-4289.
17. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
18. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
19. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-4126.
20. Coiffier B, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. ASCO. Chicago, IL; 2007; Abstract 8009 (30903).
21. Pfreundschuh M, Kloess M, Zeynalova S, et al. Six vs eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphomae (DLBCL): results of the completed RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2006; 108:Abstract 205.
22. Delarue R, Mounier N, Haioun C, et al. Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or R-CHOP 21: preliminary results of the LNH03-6B randomized GELA study. Blood 2006; 108:Abstract 2436.
23. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.
24. Glass B, Kloess M, Engert A, et al. Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL. J Clin Oncol 2005; 23:Abstract 6654 and updates.
25. Trneny M, Belada D, Vasova I, et al. Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups. Blood 2005; 106:Abstract 2444.
26. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027-5033.
27. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
28. Koehne CH, Daniel P. Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma. N Engl J Med 1996; 334:990-991.
29. Atkins CD. Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma. N Engl J Med 1996; 334:990-992.
30. De Ruysscher D, Spaas P. Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma. N Engl J Med 1996; 334:990-992.
31. McBride JA, Pugh WC. Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma. N Engl J Med 1996; 334:991-992.
32. Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997; 8:675-680.
33. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776-3785.
34. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169-1176.
35. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-122.
36. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103:3684-3688.
37. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006; 24:593-600.
38. Sieniawski M, Staak O, Glossmann JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol 2007; 86:107-115.
39. Vellenga E, Notenboom A, van't Veer M, et al. Rituximab (Mabthera) improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL. A prospective randomized HOVON Trial. Blood 2006; 108:Abstract 328.
40. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23:2240-2247.
41. Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17:iv31-iv32.
42. Tarella C, Zanni M, Magni M, et al. Benefit of rituximab addition to high-dose programs with autograft for B-cell lymphoma: a multicenter GITIL survey on 957 patients. ASH Annual Meeting Abstracts 2006; 108:207.
43. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-3127.
44. Jaeger U. A multicentre, randomized Phase III study of rituximab as maintenance treatment versus observation in patients with aggressive B-Cell lymphoma: NHL-13. Available at: http://www.clinicaltrials.gov/ct/show/ NCT00400478?order. Date accessed: 12 April 2007.
45. Haioun C, Mounier N, Emile JF, et al. Rituximab vs observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma. Final analysis of the LNH98-B3 GELA study. ASH Annual Meeting Abstracts 2005; 106:677.
46. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23:705-711.
47. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003-4008.
48. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17:1418-1423.
49. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15:283-290.
50. Hicks L, Connors JM, Mangel J, et al. Autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: extended follow-up of a matched pair analysis. ASH Annual Meeting Abstracts 2006; 108:3051.
51. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23:6409-6414.
52. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105:2677-2684.
53. Zelenetz AD. Mantle cell lymphoma: an update on management. Ann Oncol 2006; 17(suppl 4): iv12-iv14.
54. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23:1984-1992.
55. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064-3071.
56. Herold M, Haas A, Srock S, et al. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma - 4 year follow-up results of a phase III trial of the East German Study Group Hematology and Oncology (OSHO#39). Blood 2006; 108:Abstract 484 (and updates).
57. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23:7013-7023.
58. Romaguera JE, Fayad L, Rodriguez MA, et al. Blastoid Mantle Cell Lymphoma (MCL): 5-yr failure-free survival (FFS) rate of 50%, without failures after 2.5 years following treatment with rituximab (R)-hyperCVAD alternating with R-methotrexate/cytarabine (M/A). Blood 2006; 108:Abstract 2749.
59. Vose J, Loberiza FR, Bierman P, et al. Mantle cell lymphoma (MCL): induction therapy with hyper-CVAD/high-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. ASCO; 2006; Abstract 7511.
60. Schulz H, Bohlius J, Skoetz N, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706-714
61. Zelenetz AD, Advani RH, Buadi F, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma. NCCN Practice Guidelines in Oncology v2. 2006.
62. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102:749-755.
63. Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007; 92:42-49.
64. Dunleavy K, Pittaluga S, Janik J, et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome may be significantly improved by the addition of rituximab to dose-adjusted (DA)-EPOCH and obviates the need for radiation: results from a prospective study of 44 patients. Blood 2006; 108:Abstract 209.
65. Martelli M, Stefoni V, Cabras G, et al. Rituximab combined with M/VACOP-B and radiotherapy in primary mediastinal large B-cell lymphoma (PMLBCL): a prospective Italian phase II IIL study. Blood 2006; 108:Abstract 4697.
66. Vassilakopoulos TP, Angelopoulou MK, Galani Z, et al. Rituximab-CHOP (R-CHOP) and radiotherapy (RT) for primary mediastinal large B-cell lymphoma (PMLBCL). Blood 2006; 108:Abstract 2745.
67. Dunleavy K, Pittaluga S, Janik J, et al. Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-Rituximab: preliminary results showing excellent outcome. Blood 2006; 108:Abstract 2736.
68. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20:4643-4648.